Franklin Resources
SPRY icon

Franklin Resources’s ARS Pharmaceuticals SPRY Stock Holding History

Franklin Resources’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-3,278,549
Closed -$26.3M – 3327
2026
Q1 		$26.3M Buy
3,278,549
+735,452
+29% +$7.05M 0.01% 882
2025
Q4 		$29.6M Buy
2,543,097
+145,085
+6% +$1.41M 0.01% 830
2025
Q3 		$24.1M Buy
2,398,012
+569,257
+31% +$8.17M 0.01% 891
2025
Q2 		$31.9M Sell
1,828,755
-28,789
-2% -$415K 0.01% 772
2025
Q1 		$23.4M Sell
1,857,544
-118,868
-6% -$1.43M 0.01% 855
2024
Q4 		$20.9M Sell
1,976,412
-860,840
-30% -$12.1M 0.01% 902
2024
Q3 		$42.4M Sell
2,837,252
-113,711
-4% -$1.35M 0.01% 660
2024
Q2 		$25.1M Hold
2,950,963
– – 0.01% 780
2024
Q1 		$30.2M Sell
2,950,963
-1,147,534
-28% -$8.56M 0.01% 737
2023
Q4 		$22.5M Buy
4,098,497
+229,988
+6% +$1.01M 0.01% 728
2023
Q3 		$14.6M Buy
+3,868,509
New +$25.4M 0.01% 824
2021
Q3 		– Sell
-224,208
Closed -$6.93M – 2496
2021
Q2 		$6.93M Buy
224,208
+24,200
+12% +$776K ﹤0.01% 1076
2021
Q1 		$8.73M Hold
200,008
– – ﹤0.01% 1002
2020
Q4 		$9.27M Buy
+200,008
New +$6.68M ﹤0.01% 977

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Franklin Resources's SPRY Position: Q2 2026 in Review

Franklin Resources sold out of ARS Pharmaceuticals (SPRY) in Q2 2026, closing a stake of 3,278,549 shares — an estimated $26.3M sold.

Franklin Resources first reported a position in SPRY in Q4 2020 and held it in 14 quarters. The position peaked at $42.4M in Q3 2024. 206 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Franklin Resources reported no remaining ARS Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Franklin Resources sold 3,278,549 ARS Pharmaceuticals shares in Q2 2026, an estimated $26.3M.
  • Franklin Resources first reported a position in ARS Pharmaceuticals in Q4 2020 and held it in 14 quarters.
  • Franklin Resources's ARS Pharmaceuticals position peaked at $42.4M in Q3 2024.
  • 206 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Franklin Resources's 13F filing for Q2 2026, filed 13 Aug 2026.